X>YL_Q+{}(5LG@;HM-8${8|GW3M-
SYSTEM PROCESSING...
X>YL_Q+{}(5LG@;HM-8${8|GW3M-
SYSTEM PROCESSING...
Posted: 2025-04-16 23:54:42 UTC
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
Status
Last Updated
2025-04-16 23:55:38 UTC
Verified By
Rollup News
This article discusses potential healthcare and drug pricing reforms proposed in an executive order, focusing on transparency, formulary independence, and fair pricing practices.
Divorcing formularies from PBMs to ensure unbiased drug selection.
Requiring PBMs to share claims data to improve patient outcomes.
Removing specialty tiers to prevent inflated drug prices.
Ensuring fair reimbursement for pharmacies to support their viability.
Eliminating confidentiality clauses to foster direct communication between companies and manufacturers.
Stopping biosimilar substitution calls to prevent PBMs from prioritizing profit over cost-effective options.
Current formularies are influenced by economic incentives, leading to suboptimal drug choices.
Lack of data transparency hinders manufacturers' ability to improve patient results.
Specialty tiers inflate drug prices without providing additional value.
Generic Cost Ratio allows distributors to manipulate generic drug prices.
Confidentiality clauses prevent companies from negotiating better prices.
PBMs prioritize profit by promoting more expensive biosimilar versions.